Targeting cholesterol metabolism as a vulnerability of prostate cancer

The project explores what effects inhibition of cholesterol-lowering drug atorvastatin causes in the prostate and metastases in men with prostate cancer. It further studies, whether efficacy of hormone-based therapies against prostate cancer can be enhanced via simultaneous atorvastatin use in men with advanced or recurrent prostate cancer. This strategy is being tested, as prostate cancer has been shown to be reliant on cholesterol production. The project shows whether this reliance can be targeted for therapeutic benefit. The project further tests whether cholesterol and other lipids in the blood or urine can be used to predict treatment responses in advanced prostate cancer.